Musa Bali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Musa Bali has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Sukru Sindel
Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, Gazi University, Ankara, Turkey
4 shared publications - Fatma Ayerden Ebinç
Department of Nephrology, Etlik City Hospital, Ankara, Türkiye
3 shared publications - Ulver Derici
Department of Nephrology, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey
3 shared publications - Yasemin Erten
Department of Nephrology, Faculty of Medicine, Gazi University, Ankara, Turkey
3 shared publications - Galip Guz
Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Türkiye
2 shared publications - Hatice Pasaoglu
Department of Clinical Biochemistry, Gazi University Hospital, 06560 Ankara, Turkey
2 shared publications
Latest Publications
- 20 March 2019
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 23 (6) , 542-549
Oral Candida Colonization as a Risk Factor for Chronic Inflammation and Atherosclerosis in Hemodialysis Patients
The purpose of this study was to determine the prevalence of oral Candida spp. in HD patients and to investigate its relation with systemic inflammation and atherosclerosis. Microbiological samples were taken from buccal mucosa, palate, and dental prosthesis with a cotton swab. High‐sensitivity CRP (hsCRP) and IL‐6 were measured as inflammation markers. A total of 69 patients (58% male and median age 62 years) were enrolled in this study; 53.6% of total patients had oral Candida colonization. HsCRP and IL‐6 levels were found to be significantly higher in the oral Candida colonization positive group than in the Candida colonization negative group (P = 0.002 and P = 0.01, respectively). HDL levels were significantly lower in the Candida colonization positive group (P = 0.03). Peripheral artery disease (P = 0.05) and oral Candida colonization (P = 0.002) were significantly associated with inflammation. In addition to conventional risk factors such as age (P = 0.03), diabetes (P = 0.001), and peripheral artery disease (P = 0.002), oral Candida colonization is associated with coronary artery disease (P = 0.04). Oral Candida colonization might be associated with chronic inflammation and development of atherosclerosis in HD patients.
- 20 March 2019
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 23 (6) , 542-549
Oral Candida Colonization as a Risk Factor for Chronic Inflammation and Atherosclerosis in Hemodialysis Patients
The purpose of this study was to determine the prevalence of oral Candida spp. in HD patients and to investigate its relation with systemic inflammation and atherosclerosis. Microbiological samples were taken from buccal mucosa, palate, and dental prosthesis with a cotton swab. High‐sensitivity CRP (hsCRP) and IL‐6 were measured as inflammation markers. A total of 69 patients (58% male and median age 62 years) were enrolled in this study; 53.6% of total patients had oral Candida colonization. HsCRP and IL‐6 levels were found to be significantly higher in the oral Candida colonization positive group than in the Candida colonization negative group (P = 0.002 and P = 0.01, respectively). HDL levels were significantly lower in the Candida colonization positive group (P = 0.03). Peripheral artery disease (P = 0.05) and oral Candida colonization (P = 0.002) were significantly associated with inflammation. In addition to conventional risk factors such as age (P = 0.03), diabetes (P = 0.001), and peripheral artery disease (P = 0.002), oral Candida colonization is associated with coronary artery disease (P = 0.04). Oral Candida colonization might be associated with chronic inflammation and development of atherosclerosis in HD patients.
- Open Access
- 1 January 2018
- Published by Scitechnol Biosoft Pvt. Ltd. in Journal of Clinical & Experimental Nephrology
- Vol. 03 (01)
Effects of Atorvastatin and Carvedilol on Chronic Cyclosporine Nephrotoxicity in Rats
Background: To evaluate possible renoprotective effects of carvedilol and atorvastatin in CsA induced kidney injury in a rat model. Methods: Twenty-two rats were divided into five groups. Control, CsA, CsA+karvedilol, CsA+Atorvastatin, CsA +karvedilol+atorvastatin groups. Drugs were given for 21 days. Results: Serum BUN and creatinine were significantly higher in the CsA group compared to control and were significantly lower in the CsA+carvedilol+atorvastatin group compared to CsA group. Tissue MDA levels were found to be lower in group 3, 4 and 5 than in CsA group. Tissue SOD in CsA +carvedilol and CsA+atorvastatin groups were found higher than the control and CsA groups. Tissue NO levels were found to be higher only in CsA+carvedilol+atorvastatin group compared to CsA group. Apical budding, hyaline casts and apoptosis in the tubular system was significantly higher in the CsA group than in the treatment groups. Osteopontin showed strong positivity especially in the CsA group. Osteopontin density was lower in the treatment group. Conclusions: This is the first study to evaluate MDA, SOD and NO at tissue level for carvedilol in cyclosporine nephrotoxicity. Carvedilol and atorvastatin may contribute to the reduction of renal injury in chronic CsA nehropathy. These agents have provided a protective effect on renal functions especially in combined treatment.
- 1 January 2018
- Published by Scitechnol Biosoft Pvt. Ltd. in Journal of Clinical & Experimental Nephrology
- Vol. 03 (01)
Open AccessEffects of Atorvastatin and Carvedilol on Chronic Cyclosporine Nephrotoxicity in Rats
Background: To evaluate possible renoprotective effects of carvedilol and atorvastatin in CsA induced kidney injury in a rat model. Methods: Twenty-two rats were divided into five groups. Control, CsA, CsA+karvedilol, CsA+Atorvastatin, CsA +karvedilol+atorvastatin groups. Drugs were given for 21 days. Results: Serum BUN and creatinine were significantly higher in the CsA group compared to control and were significantly lower in the CsA+carvedilol+atorvastatin group compared to CsA group. Tissue MDA levels were found to be lower in group 3, 4 and 5 than in CsA group. Tissue SOD in CsA +carvedilol and CsA+atorvastatin groups were found higher than the control and CsA groups. Tissue NO levels were found to be higher only in CsA+carvedilol+atorvastatin group compared to CsA group. Apical budding, hyaline casts and apoptosis in the tubular system was significantly higher in the CsA group than in the treatment groups. Osteopontin showed strong positivity especially in the CsA group. Osteopontin density was lower in the treatment group. Conclusions: This is the first study to evaluate MDA, SOD and NO at tissue level for carvedilol in cyclosporine nephrotoxicity. Carvedilol and atorvastatin may contribute to the reduction of renal injury in chronic CsA nehropathy. These agents have provided a protective effect on renal functions especially in combined treatment.
- 1 October 2011
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 15 (5) , 658-665
Protective effect of beta-glucan on contrast induced-nephropathy and a comparison of beta-glucan with nebivolol and N-acetylcysteine in rats
It has been shown that beta-glucan (BG), which has antioxidant and immunomodulatory effects, attenuats renal ischemia–reperfusion injury. We aimed to investigate whether BG might have a preventive role against the development of contrast-induced nephropathy and to compare its effect with nebivolol (Nb) and N-acetylcysteine (NAC). Thirty-six Wistar albino female rats were randomly divided into six groups (n = 6 each): control, contrast media (CM), BG, BG + CM, Nb + CM, and NAC + CM. With the exception of control and CM groups, the others were given drugs orally once a day for 5 days. Kidney function parameters, inflammatory parameters, and serum and renal tissue oxidative stress markers were measured. Increases of serum creatinine and blood urea nitrogen levels were significantly higher (p < 0.05) in the CM group only. Absolute changes of serum creatinine levels in BG, BG + CM and Nb + CM groups were significantly lower than those in the CM group (p < 0.05). Serum levels of advanced oxidation protein products and malondialdehyde were significantly less (p < 0.05) in the BG group compared to the CM group. Histopathological lesions in the CM group were more advanced (p < 0.05). No significant differences between the BG + CM, Nb + CM and NAC + CM groups were found with regard to histopathological findings. This study suggests that BG protects or ameliorates against contrast-induced nephropathy. Its beneficial effects may be similar to or greater than those of Nb or NAC.
- 1 October 2011
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 15 (5) , 658-665
Protective effect of beta-glucan on contrast induced-nephropathy and a comparison of beta-glucan with nebivolol and N-acetylcysteine in rats
It has been shown that beta-glucan (BG), which has antioxidant and immunomodulatory effects, attenuats renal ischemia–reperfusion injury. We aimed to investigate whether BG might have a preventive role against the development of contrast-induced nephropathy and to compare its effect with nebivolol (Nb) and N-acetylcysteine (NAC). Thirty-six Wistar albino female rats were randomly divided into six groups (n = 6 each): control, contrast media (CM), BG, BG + CM, Nb + CM, and NAC + CM. With the exception of control and CM groups, the others were given drugs orally once a day for 5 days. Kidney function parameters, inflammatory parameters, and serum and renal tissue oxidative stress markers were measured. Increases of serum creatinine and blood urea nitrogen levels were significantly higher (p < 0.05) in the CM group only. Absolute changes of serum creatinine levels in BG, BG + CM and Nb + CM groups were significantly lower than those in the CM group (p < 0.05). Serum levels of advanced oxidation protein products and malondialdehyde were significantly less (p < 0.05) in the BG group compared to the CM group. Histopathological lesions in the CM group were more advanced (p < 0.05). No significant differences between the BG + CM, Nb + CM and NAC + CM groups were found with regard to histopathological findings. This study suggests that BG protects or ameliorates against contrast-induced nephropathy. Its beneficial effects may be similar to or greater than those of Nb or NAC.
- 1 January 2008
- Published by Taylor & Francis in Renal Failure
- Vol. 30 (6) , 617-623
The Relationship of Visfatin Levels to Inflammatory Cytokines and Left Ventricular Hypertrophy in Hemodialysis and Continuous Ambulatory Peritoneal Dialysis Patients
Visfatin was recently defined as an adipocytokine; however, the pathophysiological role of visfatin is not completely understood. A few studies suggest that visfatin may be a new proinflammatory adipocytokine. The aim of the present study was to compare serum visfatin levels between hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) patients and evaluate the relationship between visfatin levels to IL-6, TNF-alpha, and left ventricular hypertrophy. Serum visfatin, IL-6, and TNF-alpha levels were measured by using the ELISA method, and echocardiographic evaluations were performed in 31 hemodialysis patients, 30 CAPD patients, and 21 healthy volunteers. Serum visfatin levels were higher in the CAPD group (265.27 +/- 387.86 ng/mL) than hemodialysis (97.68 +/- 244.96 ng/mL,) and control (41.33 +/- 48.87 ng/mL) groups (p = 0.04, p = 0.01, respectively). No significant difference was observed between the hemodialysis and control groups. In univariate analysis, visfatin levels were positively correlated with IL-6 (r = 0.24, p = 0.03), TNF-alpha (r = 0.34, p = 0.002), and BMI (r = 0.26, p = 0.03) and negatively correlated with some left ventricular diastolic parameters [Em and Em/Am (r = -0.305, p = 0.01), (r = -0.251, p = 0.03), respectively]. No relationship was found between visfatin and left ventricular mass index. In the linear regression analysis, visfatin levels independently related with TNF-( (beta = 0.369, p = 0.001) and IL-6 (beta = 0.284, p = 0.015). This study has found significantly higher levels of serum visfatin in CAPD patients when compared to healthy individuals. Increased visfatin levels seem to associate with proinflammatory cytokines such as IL-6 or TNF-alpha. As for the effects of on left ventricular structure and functions, visfatin might have negative effects on left ventricular diastolic function parameters but have no effects on left ventricular mass index.
- 1 January 2008
- Published by Taylor & Francis in Renal Failure
- Vol. 30 (6) , 617-623
The Relationship of Visfatin Levels to Inflammatory Cytokines and Left Ventricular Hypertrophy in Hemodialysis and Continuous Ambulatory Peritoneal Dialysis Patients
Visfatin was recently defined as an adipocytokine; however, the pathophysiological role of visfatin is not completely understood. A few studies suggest that visfatin may be a new proinflammatory adipocytokine. The aim of the present study was to compare serum visfatin levels between hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) patients and evaluate the relationship between visfatin levels to IL-6, TNF-alpha, and left ventricular hypertrophy. Serum visfatin, IL-6, and TNF-alpha levels were measured by using the ELISA method, and echocardiographic evaluations were performed in 31 hemodialysis patients, 30 CAPD patients, and 21 healthy volunteers. Serum visfatin levels were higher in the CAPD group (265.27 +/- 387.86 ng/mL) than hemodialysis (97.68 +/- 244.96 ng/mL,) and control (41.33 +/- 48.87 ng/mL) groups (p = 0.04, p = 0.01, respectively). No significant difference was observed between the hemodialysis and control groups. In univariate analysis, visfatin levels were positively correlated with IL-6 (r = 0.24, p = 0.03), TNF-alpha (r = 0.34, p = 0.002), and BMI (r = 0.26, p = 0.03) and negatively correlated with some left ventricular diastolic parameters [Em and Em/Am (r = -0.305, p = 0.01), (r = -0.251, p = 0.03), respectively]. No relationship was found between visfatin and left ventricular mass index. In the linear regression analysis, visfatin levels independently related with TNF-( (beta = 0.369, p = 0.001) and IL-6 (beta = 0.284, p = 0.015). This study has found significantly higher levels of serum visfatin in CAPD patients when compared to healthy individuals. Increased visfatin levels seem to associate with proinflammatory cytokines such as IL-6 or TNF-alpha. As for the effects of on left ventricular structure and functions, visfatin might have negative effects on left ventricular diastolic function parameters but have no effects on left ventricular mass index.
- 1 June 2006
- Vol. 17 (2) , 144-7
Portal vein thrombosis and liver abscess due to Lactococcus lactis.
A 26-year-old man was admitted with fever and abdominal pain. Abdominal ultrasonography and Doppler ultrasound eventually revealed portal vein thrombosis and a pyogenic liver abscess (17x11x11 cm). Lactococcus lactis was isolated from a culture of the abscess material. This organism is not a common pathogen in humans. This is the first published description of portal vein thrombosis and pyogenic liver abscess due to L. lactis.
- 1 June 2006
- Vol. 17 (2) , 144-7
Portal vein thrombosis and liver abscess due to Lactococcus lactis.
A 26-year-old man was admitted with fever and abdominal pain. Abdominal ultrasonography and Doppler ultrasound eventually revealed portal vein thrombosis and a pyogenic liver abscess (17x11x11 cm). Lactococcus lactis was isolated from a culture of the abscess material. This organism is not a common pathogen in humans. This is the first published description of portal vein thrombosis and pyogenic liver abscess due to L. lactis.
- 4 July 2003
- Vol. 36, 291-300
[The presence of hepatitis C virus (HCV) infection in hemodialysis patients and determination of HCV genotype distribution].
The aim of this study was the investigation of hepatitis C virus (HCV) RNA by reverse transcriptase-polymerase chain reaction (RT-PCR), in hemodialysis patients in order to detect HCV infection, and the determination of virus genotypes in HCV positive patients. A total of 94 patients, 44 female and 50 male (mean age: 49 +/- 17 years old), who were included in hemodialysis program between 1987-1999 (0-13 years) in the Hemodialysis Units of Gazi University, School of Medicine and Ankara Etlik Hospital of Social Insurance Society, were enrolled in the study. Anti-HCV was found positive in 41 patients (43.6%), while HCV-RNA was positive in 36 patients (38.3%). Thirty three of the patients were positive for both anti-HCV and HCV-RNA, 8 were anti-HCV positive HCV-RNA negative, and 3 were anti-HCV negative HCV-RNA positive. HCV was genotyped by Restriction Fragment Length Polymorphism (RFLP) method in 36 HCV-RNA positive patients, and 28 yielded genotype 1b, and 8 showed genotype 1a pattern. PCR products from 5'UTR of HCV-RNA isolated from two patients were also sequenced to confirm the results of RFLP study. The rate of anti-HCV and HCV-RNA positivity was detected statistically higher in patients who exposed hemodialysis longer than 24 months, and in hemodialysis patients who had blood transfusion than the other groups. As a result, our findings supported that the periodic follow-up of HCV-RNA, in addition to anti-HCV would be useful for hemodialysis patients, and genotyping of HCV for the epidemiologic data.
- 4 July 2003
- Vol. 36, 291-300
[The presence of hepatitis C virus (HCV) infection in hemodialysis patients and determination of HCV genotype distribution].
The aim of this study was the investigation of hepatitis C virus (HCV) RNA by reverse transcriptase-polymerase chain reaction (RT-PCR), in hemodialysis patients in order to detect HCV infection, and the determination of virus genotypes in HCV positive patients. A total of 94 patients, 44 female and 50 male (mean age: 49 +/- 17 years old), who were included in hemodialysis program between 1987-1999 (0-13 years) in the Hemodialysis Units of Gazi University, School of Medicine and Ankara Etlik Hospital of Social Insurance Society, were enrolled in the study. Anti-HCV was found positive in 41 patients (43.6%), while HCV-RNA was positive in 36 patients (38.3%). Thirty three of the patients were positive for both anti-HCV and HCV-RNA, 8 were anti-HCV positive HCV-RNA negative, and 3 were anti-HCV negative HCV-RNA positive. HCV was genotyped by Restriction Fragment Length Polymorphism (RFLP) method in 36 HCV-RNA positive patients, and 28 yielded genotype 1b, and 8 showed genotype 1a pattern. PCR products from 5'UTR of HCV-RNA isolated from two patients were also sequenced to confirm the results of RFLP study. The rate of anti-HCV and HCV-RNA positivity was detected statistically higher in patients who exposed hemodialysis longer than 24 months, and in hemodialysis patients who had blood transfusion than the other groups. As a result, our findings supported that the periodic follow-up of HCV-RNA, in addition to anti-HCV would be useful for hemodialysis patients, and genotyping of HCV for the epidemiologic data.